{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:51:23Z","timestamp":1770216683299,"version":"3.49.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2004,7,27]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Low-molecular-weight heparin (LMWH) is recommended in the treatment of unstable angina (UA)\/non\u2013ST-segment\u2013elevation myocardial infarction (NSTEMI), but no relationship has ever been shown between anticoagulation levels obtained with LMWH treatment and clinical outcomes.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            In all, 803 consecutive patients with UA\/NSTEMI were treated with subcutaneous enoxaparin and were followed up for 30 days. The recommended dose of enoxaparin of 1 mg\/kg BID was used throughout the population except when physicians decided on dose reduction because of a history of a recent bleeding event or because of a high bleeding risk. Anti\u2013factor Xa activity was &gt;0.5 IU\/mL in 93% of patients; subtherapeutic anti-Xa levels (&lt;0.5 IU\/mL) were associated with lower doses of enoxaparin. The 30-day mortality rate was significantly associated with low anti-Xa levels (&lt;0.5 IU\/mL), with a &gt;3-fold increase in mortality compared with the patients with anti-Xa levels in the target range of 0.5 to 1.2 IU\/mL (\n            <jats:italic>P<\/jats:italic>\n            =0.004). Multivariate analysis revealed low anti-Xa activity as an independent predictor of 30-day mortality at least as strong as age, left ventricular function, and renal function. In contrast, anti-Xa activity did not predict major bleeding complications within the range of anti-Xa levels observed in this study.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            In this large unselected cohort of patients with UA\/NSTEMI patients, low anti-Xa activity on enoxaparin treatment is independently associated with 30-day mortality, which highlights the need for achieving at least the minimum prescribed anti-Xa level of 0.5 IU\/mL with enoxaparin whenever possible.\n          <\/jats:p>","DOI":"10.1161\/01.cir.0000136830.65073.c7","type":"journal-article","created":{"date-parts":[[2004,7,13]],"date-time":"2004-07-13T00:17:53Z","timestamp":1089677873000},"page":"392-398","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":133,"title":["Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin"],"prefix":"10.1161","volume":"110","author":[{"given":"G.","family":"Montalescot","sequence":"first","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Collet","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Tanguy","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ankri","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Payot","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dumaine","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Choussat","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Beygui","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gallois","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Institut de Cardiologie (G.M., J.P.C., L.P., R.D., R.C., F.B., V.G., D.T.), Department of Biostatistics (M.L.T.), and Hemostasis Laboratory (A.A.), Pitie\u0301-Salpe\u0302trie\u0300re Hospital, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.64S"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420107010"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.195"},{"key":"e_1_3_2_4_2","first-page":"530","volume":"76","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V49.2.171.171"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1645678"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000037106.76139.53"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00618-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000077530.53367.e9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.123112"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1.176"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10726"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.103.5.658"},{"key":"e_1_3_2_14_2","first-page":"8","volume":"41","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)03019-X"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00165-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(02)00131-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.122120"},{"key":"e_1_3_2_19_2","unstructured":"Enoxaparin Sodium Investigator Brochure.  12th ed.  Bridgewater NJ:  Aventis Pharma; January 31 2003."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00094-6"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00653-3"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00485-8"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(01)00455-7"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-2-199307150-00002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610303151801"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902093200604"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00487-6"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07350-X"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)80001-W"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1999.1879"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370702"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.15.1593"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00105-X"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.98.4.294"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00695-1"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.3.251"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.0000136830.65073.C7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T18:42:01Z","timestamp":1715020921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000136830.65073.C7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,27]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7,27]]}},"alternative-id":["10.1161\/01.CIR.0000136830.65073.C7"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.0000136830.65073.c7","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,27]]},"assertion":[{"value":"2004-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}